Compare RAIL & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAIL | ABOS |
|---|---|---|
| Founded | 1901 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Railroads | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.0M | 165.6M |
| IPO Year | 2005 | 2021 |
| Metric | RAIL | ABOS |
|---|---|---|
| Price | $4.69 | $0.18 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 6 |
| Target Price | ★ $10.67 | $1.00 |
| AVG Volume (30 Days) | 303.0K | ★ 5.5M |
| Earning Date | 11-09-2026 | 10-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 134.94 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $500,991,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $48.30 | N/A |
| P/E Ratio | $14.15 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.85 | $0.19 |
| 52 Week High | $14.90 | $3.60 |
| Indicator | RAIL | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 43.74 | 21.26 |
| Support Level | $3.94 | N/A |
| Resistance Level | $5.48 | $2.82 |
| Average True Range (ATR) | 0.34 | 0.03 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 43.64 | 6.47 |
FreightCar America Inc is a diversified manufacturer and supplier of railcars and railcar components. It designs and manufactures a variety of railcar types for transportation of bulk commodities and containerized freight products in North America. The company also provides railcar rebody and repair services, railcar conversion services, and supplies railcar parts. The company has two segments: Manufacturing and Aftermarket. The majority of the company's revenue is derived from the Manufacturing segment, which includes new railcar manufacturing, used railcar sales, and various conversions and rebodies. Geographically, it generates the maximum revenue from the United States.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.